British pharma giant AstraZeneca to invest $2.5 billion in new China hub

British pharma giant AstraZeneca to invest .5 billion in new China hub

Outside the Macclesfield factory of AstraZeneca.

Christopher Furlong | Getty Images News | Getty Images

British pharmaceutical giant AstraZeneca on Friday said that it will invest $2.5 billion in a research and development center in Chinese capital Beijing.

The new hub is expected to take AstraZeneca’s Beijing workforce to around 1,700 employees.

Don’t miss AstraZeneca’s CEO Pascal Soriot interview live on CNBC International at 11:30 a.m. London time / 7:30 a.m. ET.

This breaking news story is being updated.

Source

Health

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports

October 10, 2025

U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the […]

Health

At-risk teens and AI chatbot crisis: ‘You need to know what’s going on,’ warns Talkspace CEO

October 10, 2025

Talkspace has grown to be one of the largest online therapy platforms in the U.S., covering an estimated market of 200 million Americans. As the mental health platform has grown, it has also pioneered new ways to reach people in need of help with mental health issues including trauma, depression, addiction, abuse and relationships, and […]

Health

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

October 7, 2025

The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients […]